Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

F. Palandri, M. Breccia, M. Bonifacio, N. Polverelli, E.M. Elli, G. Benevolo, M. Tiribelli, E. Abruzzese, A. Iurlo, F.H. Heidel, M. Bergamaschi, A. Tieghi, M. Crugnola, F. Cavazzini, G. Binotto, A. Isidori, N. Sgherza, C. Bosi, B. Martino, R. LatagliataG. Auteri, L. Scaffidi, D. Griguolo, M. Trawinska, D. Cattaneo, L. Catani, M. Krampera, R.M. Lemoli, A. Cuneo, G. Semenzato, R. Foà, F. Di Raimondo, D. Bartoletti, M. Cavo, G.A. Palumbo, N. Vianelli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1243-1252
Number of pages10
JournalCancer
Volume126
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • investigational agents
  • myelofibrosis
  • outcome
  • ruxolitinib
  • treatment failure
  • adult
  • aged
  • allogeneic stem cell transplantation
  • anemia
  • Article
  • blast cell
  • blood toxicity
  • cancer growth
  • cancer mortality
  • cancer patient
  • cancer prognosis
  • cancer survival
  • clinical outcome
  • cohort analysis
  • controlled study
  • data base
  • disease course
  • drug withdrawal
  • Dynamic International Prognostic Score System
  • heart failure
  • high risk patient
  • human
  • infection
  • intermediate risk patient
  • karyotype
  • major clinical study
  • metastasis
  • multicenter study
  • neurologic disease
  • observational study
  • platelet count
  • pleura effusion
  • priority journal
  • prognostic assessment
  • retrospective study
  • risk factor
  • salvage therapy
  • spleen
  • thrombocytopenia
  • thrombosis
  • treatment response
  • very elderly

Cite this

Palandri, F., Breccia, M., Bonifacio, M., Polverelli, N., Elli, E. M., Benevolo, G., Tiribelli, M., Abruzzese, E., Iurlo, A., Heidel, F. H., Bergamaschi, M., Tieghi, A., Crugnola, M., Cavazzini, F., Binotto, G., Isidori, A., Sgherza, N., Bosi, C., Martino, B., ... Vianelli, N. (2020). Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 126(6), 1243-1252. https://doi.org/10.1002/cncr.32664